Trials / Unknown
UnknownNCT01266707
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Fukushima Medical University · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A\*2402 restricted patients with advanced hepatocellular carcinoma.
Detailed description
It has been required to develop new treatment modalities for patients with advanced heptatocellular carcinoma. Immunotherapy is one of the encouraging modalities for patients. We have to assess its toxicities, clinical response and immune responsiveness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | antiangiogenic paptide vaccine | for drugs include administration time frame |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2012-03-01
- Completion
- 2013-03-01
- First posted
- 2010-12-24
- Last updated
- 2010-12-24
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01266707. Inclusion in this directory is not an endorsement.